Autonomix Medical, Inc.

Autonomix Medical develops medical devices targeting disorders of the peripheral nervous system. The company's core technology is a catheter-based microchip-enabled sensing array designed to detect and differentiate neural signals in peripheral nerves. This sensing platform is being advanced for multiple clinical applications, with initial focus on pancreatic cancer patients. The company is also exploring the technology's applicability to chronic pain management, hypertension, cardiovascular conditions, and other nerve-related disorders.

The company operates as a development-stage enterprise with eight full-time employees based in The Woodlands, Texas. Autonomix Medical was incorporated in Delaware in 2014 and is traded on the Nasdaq exchange. The organization has not yet disclosed meaningful revenue streams, reflecting its stage of development focused on technology advancement and clinical application validation.